ArticleJournal of nuclear medicine : official publication, Society of Nuclear Medicine2023
PSMA-Directed Imaging and Therapy of Salivary Gland Tumors: A Single-Center Retrospective Study.
Article in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.
- Investigating the significance of SPECT/CT-SUV for monitoringBMC medical imaging · 2025Pooled it
- Prostate-specific Membrane Antigen-PET/CT in Nonprostatic Malignancies: Potential Applications in Theranostics.Clinical nuclear medicine · 2026Review
- Prostatic cancer with parotid metastases.Urology case reports · 2025Article
- A pilot study of PSMA-targeted F-18-DCFPyL PET imaging of patients with adenoid cystic carcinoma.Scientific reports · 2025Article
- Review
- PSMA-Guided Imaging and Therapy of Advanced Adenoid Cystic Carcinomas and Other Salivary Gland Carcinomas.Cancers · 2024Article
- 18 F-Choline-PET/CT for non-FDG-avid salivary gland cancer: a preliminary report.EJNMMI research · 2024Article
- Prostate-Specific Membrane Antigen Radioligand Therapy in Non-Prostate Cancers: Where Do We Stand?Bioengineering (Basel, Switzerland) · 2024Review
- The Potential Role of PSMA-Targeted PET in Salivary Gland Malignancies: An Updated Systematic Review.Diagnostics (Basel, Switzerland) · 2024Review
- Advances in Radioligand Theranostics in Oncology.Molecular diagnosis & therapy · 2024Review
- Lutetium-177-PSMA therapy for recurrent/metastatic salivary gland cancer: a prospective pilot study.Theranostics · 2024Article
- Impact of [Cancers · 2023Article
- RadioLigand Therapy with [Pharmaceuticals (Basel, Switzerland) · 2023Review
- PSMA-targeted therapy for non-prostate cancers.Frontiers in oncology · 2023Review
Corrections and comments
- Erratum issuedErrata.2024
Authors and funding
14 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We analyzed the diagnostic performance of prostate-specific membrane antigen (PSMA) PET/CT and the dosimetry, efficacy, and safety of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.